Therapy-related acute myeloid leukemia with minimal myeloid differentiation (AML-M0) associated with a t(11;19)(q23;p13.3) translocation.
Suehiro
Y
Y
Uike
N
N
Kumagawa
M
M
Goto
T
T
Muta
K
K
Kozuru
M
M
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002880:Chromosomes, Human, Pair 11; D003520:Cyclophosphamide / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000235:genetics; D004317:Doxorubicin / Q000627:therapeutic use; D015321:Gene Rearrangement / Q000187:drug effects; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000235:genetics; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D051788:Myeloid-Lymphoid Leukemia Protein; D011034:Podophyllotoxin / Q000009:adverse effects* / Q000627:therapeutic use; D011519:Proto-Oncogenes; D014157:Transcription Factors; D014178:Translocation, Genetic; D014750:Vincristine / Q000627:therapeutic use; D016335:Zinc Fingers
D000972:Antineoplastic Agents, Phytogenic; D004268:DNA-Binding Proteins; C497422:KMT2A protein, human; D014157:Transcription Factors; D051788:Myeloid-Lymphoid Leukemia Protein; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011495:Histone-Lysine N-Methyltransferase; D011034:Podophyllotoxin